Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | LPL | P06858 | 3/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12372517 | 0.90 | ALDH1A1 (0.44) | ALDH1A1LMNAARESR2HPGD | |
| SCHEMBL429388 | 0.89 | GAA (0.39) | ALDH1A1LMNAARESR2HPGD | |
| SCHEMBL426180 | 0.89 | MAPK1 (0.46) | ALDH1A1LMNAESR2HPGDNPSR1 | |
| SCHEMBL3753301 | 0.86 | ALDH1A1 (0.39) | ALDH1A1LMNAARESR2HPGD | |
| SCHEMBL430134 | 0.86 | ESR2 (0.36) | ALDH1A1LMNAARESR2LPL | |
| SCHEMBL28509985 | 0.86 | GAA (0.45) | ALDH1A1LMNAESR2LPLLIPG | |
| SCHEMBL426688 | 0.84 | LMNA (0.58) | ALDH1A1LMNAHPGDMAPTHTT | |
| SCHEMBL427904 | 0.84 | LMNA (0.37) | ALDH1A1LMNAARESR2HPGD | |
| SCHEMBL427905 | 0.83 | LMNA (0.45) | ALDH1A1LMNAESR2MAPTGAA | |
| SCHEMBL17289887 | 0.83 | TBK1 (0.41) | ALDH1A1LMNAARESR2LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705291-A1 | IKK-ALPHA INHIBITORS | Cancer Research Technology Limited (GB) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025064853-A1 | RIPK3 INHIBITORS AND METHODS OF USE | Momentum Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2025-03-20 | — | — | US | disclosed |
| WO-2024228035-A1 | IKK-ALPHA INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-11-07 | — | — | WO | disclosed |
| EP-3517536-B1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3517536-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10316049-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180370955-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2018-12-27 | — | — | US | disclosed |
| EP-3394044-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| EP-2595964-B1 | Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them | DOMAINEX LTD (GB) | 2015-04-29 | — | — | EP | disclosed |
| US-8962609-B2 | Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them | DOMAINEX LIMITED (GB) | 2015-02-24 | — | — | US | disclosed |
| US-8962609-B2 | Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them | DOMAINEX LIMITED (GB) | 2015-02-24 | — | — | US | disclosed |
| US-8962609-B2 | Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them | DOMAINEX LIMITED (GB) | 2015-02-24 | — | — | US | disclosed |
| US-20130267491-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267491-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267491-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| EP-2595964-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Domainex Limited (GB) | 2013-05-29 | — | — | EP | disclosed |
| WO-2013024282-A2 | COMPOUNDS AND THEIR USES | DOMAINEX LIMITED (GB) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012010826-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMAINEX LIMITED (GB) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | RIPK3, RIPK1, RIPK2 | ALDH1A1 4773/4885LMNA 1301/4885AR 4217/4885 |
| US-20180370955-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | ALDH1A1 4260/4885LMNA 2240/4885AR 2671/4885 |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | ALDH1A1 4260/4885LMNA 2240/4885AR 2671/4885 |
| US-10316049-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | ALDH1A1 4260/4885LMNA 2240/4885AR 2671/4885 |
| US-20130267491-A1 | PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CHUK, IKBKE, TBKBP1 | ALDH1A1 4264/4885LMNA 2583/4885AR 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.